Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06686576 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Study of Neoadjuvant QL1706 in Participants With Untreated dMMR/MSI-H Resectable Colon Cancer

StatusRecruiting
PhasePhase 3
Started
View on ClinicalTrials.gov ↗

Record History

  1. Enrollment target: 288 to 363 Interventions: CAPEOX (Drug), QL1706 (Biological) to CAPEOX/Capecitabine (Drug), QL1706 (Drug) · Study title revisedv3 Show 2 more changesShow less
    • Interventions: CAPEOX (Drug), QL1706 (Biological) to CAPEOX/Capecitabine (Drug), QL1706 (Drug)
    • Study title revised

    See this version in full on ClinicalTrials.gov ↗

  2. Trial status: Not Yet Recruiting to Recruiting Study sites: 0 to 1 · Start date changed from estimate of Dec 2024 to Dec 12, 2024v2 Show 2 more changesShow less
    • Study sites: 0 to 1
    • Start date changed from estimate of Dec 2024 to Dec 12, 2024
  3. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The goal of this clinical trial is to evaluate the efficacy of neoadjuvant QL1706 in participants with untreated T4N0 or Stage III (resectable), microsatellite instability high/ defective mismatch repair (MSI-H/dMMR) colon cancer
Trial Details
NCT Number NCT06686576
Lead Sponsor Qilu Pharmaceutical Co., Ltd.
Conditions Colon Cancer
Enrollment 363 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov